{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:45Z","timestamp":1792114125092,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T00:00:00Z","timestamp":1398643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/ni.2885","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T17:17:28Z","timestamp":1398705448000},"page":"562-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":244,"title":["USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses"],"prefix":"10.1038","volume":"15","author":[{"given":"Qiang","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan S","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S","family":"Watowich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Cong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,28]]},"reference":[{"key":"BFni2885_CR1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1731","volume":"5","author":"YC Liu","year":"2005","unstructured":"Liu, Y.C., Penninger, J. & Karin, M. Immunity by ubiquitylation: a reversible process of modification. Nat. Rev. Immunol. 5, 941\u2013952 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"BFni2885_CR2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrc3120","volume":"11","author":"S Lipkowitz","year":"2011","unstructured":"Lipkowitz, S. & Weissman, A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11, 629\u2013643 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"BFni2885_CR3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425\u2013479 (1998).","journal-title":"Annu. Rev. Biochem."},{"key":"BFni2885_CR4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molcel.2009.01.014","volume":"33","author":"ZJ Chen","year":"2009","unstructured":"Chen, Z.J. & Sun, L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275\u2013286 (2009).","journal-title":"Mol. Cell"},{"key":"BFni2885_CR5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrm3394","volume":"13","author":"Y Kulathu","year":"2012","unstructured":"Kulathu, Y. & Komander, D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13, 508\u2013523 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFni2885_CR6","doi-asserted-by":"crossref","first-page":"e1487","DOI":"10.1371\/journal.pone.0001487","volume":"3","author":"W Li","year":"2008","unstructured":"Li, W. et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 3, e1487 (2008).","journal-title":"PLoS ONE"},{"key":"BFni2885_CR7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-12-0053","volume":"19","author":"Q Li","year":"2013","unstructured":"Li, Q. & Lozano, G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 19, 34\u201341 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFni2885_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade, M., Li, Y.C. & Wahl, G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83\u201396 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"BFni2885_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","volume":"49","author":"S Shangary","year":"2009","unstructured":"Shangary, S. & Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223\u2013241 (2009).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFni2885_CR10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.biochem.78.082307.091526","volume":"78","author":"FE Reyes-Turcu","year":"2009","unstructured":"Reyes-Turcu, F.E., Ventii, K.H. & Wilkinson, K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363\u2013397 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"BFni2885_CR11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander, D., Clague, M.J. & Urbe, S. Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10, 550\u2013563 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFni2885_CR12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nri2337","volume":"8","author":"SC Sun","year":"2008","unstructured":"Sun, S.C. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8, 501\u2013511 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"BFni2885_CR13","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2011.443","volume":"31","author":"JM Fraile","year":"2012","unstructured":"Fraile, J.M., Quesada, V., Rodriguez, D., Freije, J.M. & Lopez-Otin, C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 31, 2373\u20132388 (2012).","journal-title":"Oncogene"},{"key":"BFni2885_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-065X.2012.01100.x","volume":"246","author":"EW Harhaj","year":"2012","unstructured":"Harhaj, E.W. & Dixit, V.M. Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 246, 107\u2013124 (2012).","journal-title":"Immunol. Rev."},{"key":"BFni2885_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/geno.1999.5879","volume":"59","author":"RT Baker","year":"1999","unstructured":"Baker, R.T., Wang, X.W., Woollatt, E., White, J.A. & Sutherland, G.R. Identification, functional characterization, and chromosomal localization of USP15, a novel human ubiquitin-specific protease related to the UNP oncoprotein, and a systematic nomenclature for human ubiquitin-specific proteases. Genomics 59, 264\u2013274 (1999).","journal-title":"Genomics"},{"key":"BFni2885_CR16","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1128\/JVI.00605-09","volume":"83","author":"RM Vos","year":"2009","unstructured":"Vos, R.M., Altreuter, J., White, E.A. & Howley, P.M. The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J. Virol. 83, 8885\u20138892 (2009).","journal-title":"J. Virol."},{"key":"BFni2885_CR17","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/ncb2346","volume":"13","author":"M Inui","year":"2011","unstructured":"Inui, M. et al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat. Cell Biol. 13, 1368\u20131375 (2011).","journal-title":"Nat. Cell Biol."},{"key":"BFni2885_CR18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm.2619","volume":"18","author":"PJ Eichhorn","year":"2012","unstructured":"Eichhorn, P.J. et al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat. Med. 18, 429\u2013435 (2012).","journal-title":"Nat. Med."},{"key":"BFni2885_CR19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cub.2005.05.059","volume":"15","author":"BK Hetfeld","year":"2005","unstructured":"Hetfeld, B.K. et al. The zinc finger of the CSN-associated deubiquitinating enzyme USP15 is essential to rescue the E3 ligase Rbx1. Curr. Biol. 15, 1217\u20131221 (2005).","journal-title":"Curr. Biol."},{"key":"BFni2885_CR20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.188.9.1651","volume":"188","author":"AE Wakil","year":"1998","unstructured":"Wakil, A.E., Wang, Z.E., Ryan, J.C., Fowell, D.J. & Locksley, R.M. Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell type 1 development. J. Exp. Med. 188, 1651\u20131656 (1998).","journal-title":"J. Exp. Med."},{"key":"BFni2885_CR21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"JE Smith-Garvin","year":"2009","unstructured":"Smith-Garvin, J.E., Koretzky, G.A. & Jordan, M.S. T cell activation. Annu. Rev. Immunol. 27, 591\u2013619 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"BFni2885_CR22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V98.5.1480","volume":"98","author":"A Kiani","year":"2001","unstructured":"Kiani, A. et al. Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood 98, 1480\u20131488 (2001).","journal-title":"Blood"},{"key":"BFni2885_CR23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472\u2013484 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"BFni2885_CR24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.molcel.2005.10.033","volume":"20","author":"M Yoeli-Lerner","year":"2005","unstructured":"Yoeli-Lerner, M. et al. Akt blocks breast cancer cell motility and invasion through the transcription factor. NFAT. Mol. Cell 20, 539\u2013550 (2005).","journal-title":"Mol. Cell"},{"key":"BFni2885_CR25","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1021\/bi200726e","volume":"50","author":"S Harper","year":"2011","unstructured":"Harper, S., Besong, T.M., Emsley, J., Scott, D.J. & Dreveny, I. Structure of the USP15 N-terminal domains: a beta-hairpin mediates close association between the DUSP and UBL domains. Biochemistry 50, 7995\u20138004 (2011).","journal-title":"Biochemistry"},{"key":"BFni2885_CR26","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1535-7163.MCT-08-0063","volume":"7","author":"J Kitagaki","year":"2008","unstructured":"Kitagaki, J., Agama, K.K., Pommier, Y., Yang, Y. & Weissman, A.M. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol. Cancer Ther. 7, 2445\u20132454 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"BFni2885_CR27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1101\/gad.1941710","volume":"24","author":"JJ Manfredi","year":"2010","unstructured":"Manfredi, J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 24, 1580\u20131589 (2010).","journal-title":"Genes Dev."},{"key":"BFni2885_CR28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848 (2004).","journal-title":"Science"},{"key":"BFni2885_CR29","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1073\/pnas.0308411100","volume":"101","author":"H Ovaa","year":"2004","unstructured":"Ovaa, H. et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc. Natl. Acad. Sci. USA 101, 2253\u20132258 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni2885_CR30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/bbrc.1996.0575","volume":"221","author":"Y Take","year":"1996","unstructured":"Take, Y., Kumano, M., Teraoka, H., Nishimura, S. & Okuyama, A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem. Biophys. Res. Commun. 221, 207\u2013212 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFni2885_CR31","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/cdd.2010.18","volume":"17","author":"CF Cheok","year":"2010","unstructured":"Cheok, C.F., Kua, N., Kaldis, P. & Lane, D.P. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 17, 1486\u20131500 (2010).","journal-title":"Cell Death Differ."},{"key":"BFni2885_CR32","first-page":"21","volume":"20","author":"WW Overwijk","year":"2001","unstructured":"Overwijk, W.W. & Restifo, N.P. B16 as a mouse model for human melanoma. Curr. Protoc. Immunol. 20, 21 (2001).","journal-title":"Curr. Protoc. Immunol."},{"key":"BFni2885_CR33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","volume":"222","author":"R Kennedy","year":"2008","unstructured":"Kennedy, R. & Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222, 129\u2013144 (2008).","journal-title":"Immunol. Rev."},{"key":"BFni2885_CR34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature737","volume":"416","author":"M Li","year":"2002","unstructured":"Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648\u2013653 (2002).","journal-title":"Nature"},{"key":"BFni2885_CR35","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/onc.2009.427","volume":"29","author":"N Kon","year":"2010","unstructured":"Kon, N. et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29, 1270\u20131279 (2010).","journal-title":"Oncogene"},{"key":"BFni2885_CR36","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.bbamcr.2012.05.006","volume":"1823","author":"CM Loch","year":"2012","unstructured":"Loch, C.M. & Strickler, J.E. A microarray of ubiquitylated proteins for profiling deubiquitylase activity reveals the critical roles of both chain and substrate. Biochim. Biophys. Acta 1823, 2069\u20132078 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFni2885_CR37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237\u2013251 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"BFni2885_CR38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/378203a0","volume":"378","author":"R Montes de Oca Luna","year":"1995","unstructured":"Montes de Oca Luna, R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203\u2013206 (1995).","journal-title":"Nature"},{"key":"BFni2885_CR39","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/ni.2090","volume":"12","author":"M Chang","year":"2011","unstructured":"Chang, M. et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat. Immunol. 12, 1002\u20131009 (2011).","journal-title":"Nat. Immunol."},{"key":"BFni2885_CR40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1084\/jem.20062694","volume":"204","author":"WW Reiley","year":"2007","unstructured":"Reiley, W.W. et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204, 1475\u20131485 (2007).","journal-title":"J. Exp. Med."},{"key":"BFni2885_CR41","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1073\/pnas.91.4.1346","volume":"91","author":"S-C Sun","year":"1994","unstructured":"Sun, S.-C., Ganchi, P.A., Beraud, C., Ballard, D.W. & Greene, W.C. Autoregulation of the NF-\u03baB transactivator Rel A (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc. Natl. Acad. Sci. USA 91, 1346\u20131350 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni2885_CR42","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/embor.2009.69","volume":"10","author":"GC Hassink","year":"2009","unstructured":"Hassink, G.C. et al. The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Rep. 10, 755\u2013761 (2009).","journal-title":"EMBO Rep."},{"key":"BFni2885_CR43","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1172\/JCI65459","volume":"122","author":"Y Lu","year":"2012","unstructured":"Lu, Y. et al. Th9 cells promote antitumor immune responses in vivo. J. Clin. Invest. 122, 4160\u20134171 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFni2885_CR44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0022-1759(03)00191-1","volume":"278","author":"ME Cvijic","year":"2003","unstructured":"Cvijic, M.E., Xiao, G. & Sun, S.C. Study of T-cell signaling by somatic cell mutagenesis and complementation cloning. J. Immunol. Methods 278, 293\u2013304 (2003).","journal-title":"J. Immunol. Methods"},{"key":"BFni2885_CR45","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.4049\/jimmunol.168.4.1528","volume":"168","author":"KE Foulds","year":"2002","unstructured":"Foulds, K.E. et al. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168, 1528\u20131532 (2002).","journal-title":"J. Immunol."},{"key":"BFni2885_CR46","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1038\/sj.onc.1208427","volume":"24","author":"LA Edwards","year":"2005","unstructured":"Edwards, L.A. et al. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB\/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24, 3596\u20133605 (2005).","journal-title":"Oncogene"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ni.2885.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ni.2885","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ni.2885.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:05:31Z","timestamp":1684447531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ni.2885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,28]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["BFni2885"],"URL":"https:\/\/doi.org\/10.1038\/ni.2885","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,28]]},"assertion":[{"value":"19 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}